Ownership history in UBS Group AG · 7 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in BIONDVAX PHARMACEUTICALS LTD (SCNI). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | ADDED | 1,748 | +1,740 | +21750.0% | 0.00% | $1K | $0.71 |
| 2025 Q3 | REDUCED | 8 | -12,048 | -99.9% | 0.00% | $10 | $1.26 |
| 2025 Q2 | REDUCED | 12,056 | -2,876 | -19.3% | 0.00% | $27K | $2.28 |
| 2025 Q1 | REDUCED | 14,932 | -8,556 | -36.4% | 0.00% | $40K | $2.69 |
| 2024 Q4 | ADDED | 23,488 | +23,458 | +78193.3% | 0.00% | $79K | $3.35 |
| 2024 Q3 | REDUCED | 30 | -181 | -85.8% | 0.00% | $104 | $3.45 |
| 2024 Q2 | INITIATED | 211 | — | — | 0.00% | $586 | — |
As of 2025 Q4 — sorted by position size